NCT04693195

A Multiple-Dose Study of BLU-5937 in Chronic Pruritus Associated With Atopic Dermatitis

A Randomized, Double-Blind, Placebo-Controlled, Parallel Study to Evaluate the Efficacy, Safety, and Tolerability of BLU-5937 for the Treatment of Chronic Pruritus in Adult Subjects With Atopic Dermatitis

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 142 (actual)
• Sponsor: Bellus Health Inc. - a GSK company · Industry
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

This is a multicenter, randomized, double-blind, placebo-controlled, parallel design study of BLU-5937 for the treatment of chronic pruritus in adult subjects with atopic dermatitis (AD).

Detailed description

The study will consist of a 37-day Screening period (including a 7-day Run-In period), a 4-week Treatment period followed by a Follow-Up visit approximately 2 weeks after the last dose of study drug.

Conditions

• Chronic Pruritus
• Atopic Dermatitis

Interventions

Type	Name	Description
DRUG	BLU-5937	Oral administration of BLU-5937 tablets
DRUG	Placebo	Oral administration of matching placebo for BLU-5937 tablets

Timeline

• Start date: 2020-12-09
• Primary completion: 2021-10-04
• Completion: 2021-10-12
• First posted: 2021-01-05
• Last updated: 2022-10-17

Locations

33 sites across 2 countries: United States, Canada

Regulatory

• FDA-regulated drug study